Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin (BCG), the active ingredient in Oncotice, is a live‑attenuated bacterial vaccine presented as a suspension for intravesical use. It is employed in the treatment of non‑muscle‑invasive bladder cancer, where it reduces recurrence and progression risk.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oncotice is a live‑attenuated BCG vaccine used in the uro‑oncology pathway to stimulate local immune responses against bladder tumours. - Non‑muscle‑invasive bladder cancer (NMIBC): helps prevent tumour recurrence and progression after transurethral resection. - Carcinoma in situ of the bladder: induces immune‑mediated tumour regression. - High‑risk recurrent NMIBC: provides additional prophylactic benefit when standard intravesical therapy is insufficient.

Adverse reactions are primarily local bladder irritation and systemic immune responses.

Common Side Effects: - Dysuria: painful urination during or after instillation. - Urinary frequency: increased urge to void. - Hematuria: presence of blood in urine. - Low‑grade fever: mild temperature elevation. - Fatigue: general tiredness. - Mild cystitis‑like symptoms.

Serious or Rare Side Effects: - Systemic BCG infection (disseminated mycobacterial disease). - Severe allergic reaction or anaphylaxis. - Persistent high‑grade fever. - Hepatitis or liver enzyme elevation. - Sepsis or septic shock. - Autoimmune phenomena such as Guillain‑Barré syndrome.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for adverse events. - Contraindication: active tuberculosis or immunosuppression: increased risk of disseminated infection. - Prior BCG therapy reaction: assess tolerance before re‑challenge. - Bladder integrity: avoid instillation if recent traumatic catheterisation or surgery. - Concurrent immunomodulators: consider risk of enhanced systemic effects. - Pregnancy and lactation: avoid use; insufficient safety data. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

BCG interacts with several therapeutic classes; awareness helps prevent amplified immune reactions.

Major Interactions (Avoid): - Systemic chemotherapy agents (e.g., mitomycin C, doxorubicin): may increase systemic toxicity. - High‑dose corticosteroids: suppress intended immune response. - Live viral vaccines: concurrent administration can cause uncontrolled infection.

Moderate Interactions (Monitor Closely): - Immunomodulatory drugs (e.g., checkpoint inhibitors, interferon‑alpha): may augment immune‑mediated adverse events. - Antifungal azoles (e.g., fluconazole): potential pharmacokinetic interactions. - Anticoagulants: monitor for rare bleeding complications linked to severe cystitis.